The Third Survey of Prescription Pattern of Psychotropic Drugs in China
NCT ID: NCT01668810
Last Updated: 2012-08-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
7000 participants
OBSERVATIONAL
2012-07-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Beijing region
include six hospitals
No interventions assigned to this group
Guangdong Province
include 3 hospitals
No interventions assigned to this group
Jiangsu province
include 3 hospitals
No interventions assigned to this group
Hebei province
include 6 hospitals
No interventions assigned to this group
Hubei Province
include 7 hospitals
No interventions assigned to this group
Shanxi province
include 3 hospitals
No interventions assigned to this group
Jiangxi province
include 3 hospitals
No interventions assigned to this group
Jilin province
include 6 hospitals
No interventions assigned to this group
Sichuan province
include 3 hospitals
No interventions assigned to this group
Shaanxi province
include 3 hospitals
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xian-Janssen Pharmaceutical Ltd.
INDUSTRY
Peking University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Si Tianmei
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xin Yu, MD.
Role: STUDY_CHAIR
Peking University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of mental health, Peking University
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tianmei Si, PhD.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RISSCH4255
Identifier Type: -
Identifier Source: org_study_id